AAAAAA
Results: 26-40/40
Authors:
Daelemans, D
Schols, D
Witvrouw, M
Pannecouque, C
Hatse, S
van Dooren, S
Hamy, F
Klimkait, T
De Clercq, E
Vandamme, AM
Citation: D. Daelemans et al., A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry, MOLEC PHARM, 57(1), 2000, pp. 116-124
Authors:
Allain, JP
Dong, Y
Vandamme, AM
Moulton, V
Salemi, M
Citation: Jp. Allain et al., Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: Studies of infected donor-recipient clusters, J VIROLOGY, 74(6), 2000, pp. 2541-2549
Authors:
Vandamme, AM
Witvrouw, M
Pannecouque, C
Balzarini, J
Van Laethem, K
Schmit, JC
Desmyter, J
De Clercq, E
Citation: Am. Vandamme et al., Evaluating clinical isolates for their phenotypic and genotypic resistanceagainst anti-HIV drugs, METH MOL M, 24, 2000, pp. 223-258
Authors:
Van Laethem, K
Van Vaerenbergh, K
Schmit, JC
Sprecher, S
Hermans, P
De Vroey, V
Schuurman, R
Harrer, T
Witvrouw, M
Van Wijngaerden, E
Stuyver, L
Van Ranst, M
Desmyter, J
De Clercq, E
Vandamme, AM
Citation: K. Van Laethem et al., Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations, J ACQ IMM D, 22(2), 1999, pp. 107-118
Authors:
Walter, H
Schmidt, B
Korn, K
Vandamme, AM
Harrer, T
Uberla, K
Citation: H. Walter et al., Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors, J CLIN VIRO, 13(1-2), 1999, pp. 71-80
Authors:
Van Brussel, M
Salemi, M
Liu, HF
Goubau, P
Desmyter, J
Vandamme, AM
Citation: M. Van Brussel et al., The discovery of two new divergent STLVs has implications for the evolution and epidemiology of HTLVs, REV MED VIR, 9(3), 1999, pp. 155-170
Authors:
Daelemans, D
Vandamme, AM
De Clercq, E
Citation: D. Daelemans et al., Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy, ANTIVIR CHE, 10(1), 1999, pp. 1-14
Authors:
Oelrichs, RB
Vandamme, AM
Van Laethem, K
Debyser, Z
McCutchan, FE
Deacon, NJ
Citation: Rb. Oelrichs et al., Full-length genomic sequence of an HIV type 1 subtype G from Kinshasa, AIDS RES H, 15(6), 1999, pp. 585-589
Authors:
Salemi, M
Vandamme, AM
Desmyter, J
Casoli, C
Bertazzoni, U
Citation: M. Salemi et al., The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy, GENE, 234(1), 1999, pp. 11-21
Authors:
Witvrouw, M
Pannecouque, C
Van Laethem, K
Desmyter, J
De Clercq, E
Vandamme, AM
Citation: M. Witvrouw et al., Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV, AIDS, 13(12), 1999, pp. 1477-1483
Authors:
Salemi, M
Lewis, M
Egan, JF
Hall, WW
Desmyter, L
Vandamme, AM
Citation: M. Salemi et al., Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes, P NAS US, 96(23), 1999, pp. 13253-13258
Authors:
Van Dooren, S
Gotuzzo, E
Salemi, M
Watts, D
Audenaert, E
Duwe, S
Ellerbrok, H
Grassmann, R
Hagelberg, E
Desmyter, J
Vandamme, AM
Citation: S. Van Dooren et al., Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] in Latin America (vol 79, pg 2695, 1998), J GEN VIROL, 80, 1999, pp. 1087-1087
Authors:
Vandamme, AM
Van Laethem, K
Schmit, JC
Van Wijngaerden, E
Reynders, M
Debyser, Z
Witvrouw, M
Van Ranst, M
De Clercq, E
Desmyter, J
Citation: Am. Vandamme et al., Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood, EUR J CL IN, 29(5), 1999, pp. 445-452
Authors:
Vandamme, AM
Van Laethem, K
De Clercq, E
Citation: Am. Vandamme et al., Managing resistance to anti-HIV drugs - An important consideration for effective disease management, DRUGS, 57(3), 1999, pp. 337-361
Authors:
Weber, J
Taylor, G
Chieco-Bianchi, L
de The, G
Weiss, R
Goubau, P
Ebbesen, P
Gessain, A
Ozden, S
Brahic, M
Dokhelar, MC
Guillemain, B
von der Helm, K
Bertazzoni, U
Liso, V
Varnier, O
Saracco, A
Huisman, JG
Bangham, CRM
Catovsky, D
Matutes, E
Dalgleish, A
Lever, AML
Mortimer, P
Tosswill, J
Noone, A
Schulz, T
Vandamme, AM
Carton, H
Willems, L
Kirkhofs, P
Wantzin, P
Christiansen, CB
Hall, W
Mamoun, R
Coste, J
Hermine, O
Gout, O
Dodon, MD
Wattel, E
Desgranges, C
Giraudon, P
Pauli, G
Niewiesk, S
Kucherer, C
Khazaie, K
Grassmann, R
Hatzakis, A
Casoli, C
Wicks, R
Manca, F
Galli, M
Ferrante, P
Boeri, E
Lillo, F
Macchi, B
Avillez, F
Caetano, M
Soriano, V
Illa, I
Horal, P
Andersson, S
Krook, A
Daenke, S
Breuer, J
Kelsey, S
Nightingale, S
Pagliuca, T
Bain, B
Brighty, D
Rudge, P
Ades, T
Cann, AJ
Citation: J. Weber et al., The HTLV European Research Network (HERN) Steering Committee, BIOM HLTH R, 24, 1998, pp. 266-271